key: cord-0775948-l8vkzbh0 authors: Shah, Pinak B.; Welt, Frederick G.P.; Mahmud, Ehtisham; Phillips, Alistair; Kleiman, Neal S.; Young, Michael N.; Sherwood, Matthew; Batchelor, Wayne; Wang, Dee Dee; Davidson, Laura; Wyman, Janet; Kadavath, Sabeeda; Szerlip, Molly; Hermiller, James; Fullerton, David; Anwaruddin, Saif title: Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement date: 2020-04-06 journal: JACC. Cardiovascular interventions DOI: 10.1016/j.jcin.2020.04.001 sha: 9adac2f346e0fee86855fce43415bc9a84bd4410 doc_id: 775948 cord_uid: l8vkzbh0 Abstract The COVID-19 pandemic has strained health care resources around the world causing many institutions to curtail or stop elective procedures. This has resulted in the inability to care for patients valvular and structural heart disease (SHD) in a timely fashion potentially placing these patients at increased risk for adverse cardiovascular complications including congestive heart failure and death. The effective triage of these patients has become challenging in the current environment as clinicians have had to weigh the risk of bringing susceptible patients into the hospital environment during the COVID-19 pandemic versus the risk of delaying a needed procedure. In this document, we suggest guidelines as to how to triage patients in need of SHD interventions and provide a framework of how to decide when it may be appropriate to proceed with intervention despite the ongoing pandemic. In particular, we address the triage of patients in need of trans-catheter aortic valve replacement and percutaneous mitral valve repair. We also address procedural issues and considerations for the function of structural heart disease teams during the COVID-19 pandemic. The COVID-19 pandemic has strained health care resources around the world causing many institutions to curtail or stop elective procedures. This has resulted in the inability to care for patients valvular and structural heart disease (SHD) in a timely fashion potentially placing these patients at increased risk for adverse cardiovascular complications including congestive heart failure and death. The effective triage of these patients has become challenging in the current environment as clinicians have had to weigh the risk of bringing susceptible patients into the hospital environment during the COVID-19 pandemic versus the risk of delaying a needed procedure. In this document, we suggest guidelines as to how to triage patients in need of SHD interventions and provide a framework of how to decide when it may be appropriate to proceed with intervention despite the ongoing pandemic. In particular, we address the triage of patients in need of trans-catheter aortic valve replacement and percutaneous mitral valve repair. We also address procedural issues and considerations for the function of structural heart disease teams during the COVID-19 pandemic. Coronavirus delayed. Therefore, decisions regarding timing of SHD interventions must consider the risk of delaying the procedure, the risk for the patient of COVID-19 exposure outside of home shelter, and utilization of limited hospital resources. Compounding this challenge is the geographical variation in the peak of the pandemic within the United States, and the significant delay in restoration of normal health care operations after the immediate threat has passed. The length of this delay is unknown but could be many months subsequent to the peak which poses distinct challenges for rescheduling procedures. The purpose of this document is to provide a framework for SHD teams to triage patients in need of SHD intervention during the COVID-19 pandemic and to discuss evaluation and procedural considerations for these patients. The general priorities are: a) to minimize exposure to coronavirus for SHD patients and the structural interventional team; b) maintain high quality and durable structural interventional outcomes in those who do require a procedure during the pandemic; c) reduce the risk that these SHD patients use resources that might be needed for COVID-19 patients; and d) prevent delay of intervention in patients at particularly high risk for clinical deterioration, heart failure, and death. It is understood that for any individual patient, local clinical judgment based on the impact of the COVID-19 pandemic in the region and institution should ultimately guide the evaluation and treatment pathway. Given advanced age and comorbidities, many patients with severe symptomatic aortic stenosis (AS) are at increased risk for COVID-19 complications and death. However, multiple studies have also shown higher mortality among patients with severe symptomatic AS with a delay in treatment (2,3) over several months to years rather than weeks. This writing group proposes the following for the timing of TAVR for severe AS during the COVID-19 pandemic: For inpatients with severe symptomatic AS associated with a reduction in EF thought secondary to AS, presence of class III-IV congestive heart failure (CHF), or syncope secondary to AS, TAVR should be considered to decrease the risk of clinical deterioration, prolonged hospital stay, or repeat hospitalization. It would be reasonable to schedule TAVR for outpatients with severe to critical aortic stenosis and class III-IV CHF symptoms. For patients with class I-II NYHA CHF symptoms and quantitative measures of valve severity that indicate a critically tight valve, it is reasonable to consider either urgent TAVR or close outpatient virtual monitoring by the valve coordinator. Data to date are not robust enough to give firm recommendations but features that warrant consideration of TAVR include particularly high peak or mean gradient, very small calculated aortic valve area, or very low dimensionless index. For truly asymptomatic patients, it is reasonable to postpone consideration of TAVR for three months or until after hospital operations resume elective procedures. Close outpatient monitoring, possibly via telehealth, should continue for all patients with severe AS. TAVR centers should establish a system that provides weekly telephone follow-up for patients whose procedures have been deferred. It is expected that some of these patients will develop worsening of their symptoms and will require the procedure to be performed more urgently during the pandemic. We recommend that the TAVR team convene virtually on at least a weekly basis to review the status of patients on the "waiting" list. A single interventional cardiologist and cardiac surgeon should assume a leadership position and be given the authority to arbitrate challenging cases. No triage system can accurately identify all patients who may be safely deferred; the triage system will need to be individualized to each medical center, institutional valve program, patient population served, and the pandemic's local impact. There should be no compromise in the quality of interventional care provided to TAVR patients during the COVID-19 pandemic. The majority of TAVR procedures can be performed using a minimalist approach with moderate conscious sedation. Recent data from the TVT registry has shown a steady increase in the utilization of moderate sedation for TAVR with improved safety and recovery (4, 5) . The majority of TAVR procedures do not require intensive care unit recovery after the procedure, and this is important as critical care beds will be limited during the COVID-19 crisis in parts of the country. PCI should only be performed prior to TAVR when the coronary artery disease is contributing to the patient's clinical presentation or would pose high risk for the TAVR procedure. Otherwise, PCI may be safely deferred. The majority of percutaneous mitral valve repair (edge-to-edge repair) can be safely deferred. The following groups of patients should be considered for treatment with edge-to-edge repair during the COVID-19 pandemic: It is the responsibility of the procedural team to keep in contact with the patients who are deferred on a weekly basis to ensure that there has been no decompensation requiring earlier intervention. ViV TMVR is the only other transcatheter mitral valve intervention hat is currently United States FDA approved. Since these procedures are resource intensive, they should be deferred until after the COVID-19 pandemic has adequately resolved providing such mitral valve patients can be sufficiently managed on medical therapy in the interim. ViV TMVR during the COVID-19 pandemic should be considered for patients with severe bioprosthetic mitral stenosis/regurgitation who are inpatients with CHF or outpatients who have had a hospitalization for CHF within 30 days despite optimized GDMT. Transcatheter mitral valve-in-ring (ViR TMVR) and valve-in-mitral annular calcification (ViMAC TMVR) are off-label procedures and are at a much higher risk for complications that may prolong hospitalization (8, 9) . These latter procedures should be generally avoided during the COVID-19 pandemic. PVL closure (particularly mitral) is generally a lengthy procedure and requires general anesthesia and transesophageal echocardiography (TEE). Patients who have significant PVL but with symptoms that can be managed medically should be deferred until after the moratorium on nonessential procedures has been removed. Patients who should be considered for PVL closure during the COVID-19 pandemic are inpatients with CHF and/or hemolysis. Other commonly performed SHD interventions include patent foramen ovale (PFO) closure, atrial septal defect (ASD) closure, left atrial appendage (LAAO) occlusion and alcohol septal ablation for hypertrophic cardiomyopathy. These procedures treat conditions that rarely result in hospitalization or death without the procedure over the shortterm. For these reasons, these procedures should be deferred until it is deemed safe to resume performing non-emergent procedures in the procedural suites. To offset the risk of particulate aerosolization, pre-procedural TEE should be limited in use. If a patient is planned for an emergent percutaneous mitral valve repair procedure, on- SHD clinics and procedures are sustained through a multidisciplinary heart team process. This team consists of interventional cardiologists, cardiac surgeons, cardiac imaging specialists, anesthesiologists, and nurse specialists. Depending on the workflows and potential exposure both within the hospital (as rates of exposure-based infections to health care workers remain high during this pandemic) and out of the workplace, team members may need to be quarantined or treated for illness. This may lead to interruptions in scheduled cases depending on the length of absence. Consideration of clustered scheduling using designated teams may be helpful in addressing interruptions due to temporary absence of team personnel. Strong consideration should be given for deferral of all clinical trial cases until after adequate resolution of the COVID-19 pandemic. This recommendation should also be determined in accordance with institutional research policies as several institutions have limited enrollment in clinical trials to only studies of life-saving therapies during the pandemic. If patients being considered for clinical investigation become clinically unstable during the Temporal trends and clinical consequences of wait times for transcatheter aortic valve replacement: a population study Association between wait time for transcatheter aortic valve replacement and early postprocedural outcomes Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: variation in practice and outcomes Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: insights from the national ACC/STS TVT registry Complete revascularization is not a prerequisite for success in current transcatheter aortic valve implantation practice Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy: a systematic review and meta-analysis One-year outcomes of trans-catheter mitral valve replacement in patients with severe mitral annular calcification Thirty-day outcomes of transcatheter mitral valve replacement for degenerated mitral bioprostheses (valve-in-valve), failed surgical rings (valve-in-rings), and native valve with severe mitral annular calcification (valve-in-mitral annular calcification) in the United States COVID-19 pandemic, they should be treated using commercially approved therapies. Continued follow-up of patients already enrolled and treated should be maintained. The present COVID-19 pandemic has led the heart team to re-prioritize many SHD interventions considering the ongoing surge of other critically ill patients. The current pandemic will require physicians to make challenging decisions regarding the proper triage and deferral of patients as necessary. There remains significant uncertainty regarding the trajectory of the COVID-19 pandemic, but based on experience of other nations, the United States health care system must be prepared for a surge of critically ill patients in the coming weeks. A coordinated multidisciplinary effort needs to occur to safely defer and monitor SHD patients requiring interventional therapies.